<DOC>
	<DOCNO>NCT02520921</DOCNO>
	<brief_summary>To compare treatment enteric coat aspirin twice day ( 100 mg morning 100 mg evening ) versus enteric coat aspirin 100 mg per day composite end-point ischemic event diabetic patient acute coronary syndrome . It expect aspirin take twice day reduce occurrence new ischemic event acute coronary syndrome diabetic patient .</brief_summary>
	<brief_title>Aspirin Twice Day Patients With Diabetes Acute Coronary Syndrome</brief_title>
	<detailed_description>Patients show high persistent platelet reactivity aspirin increasingly become issue clinical concern . Several study suggest give aspirin frequently effective reduce aspirin high persistent platelet reactivity , especially diabetic patient . The aim study evaluate low dose aspirin twice day ( compare day ) reduction ischemic event diabetic patient acute coronary syndrome . Experimental Design : A multicenter , randomize , parallel group compare aspirin give twice day compare per day diabetic patient acute coronary syndrome . Primary objective : To compare treatment enteric coat aspirin twice day ( 100 mg morning 100 mg evening ) versus enteric coat aspirin 100 mg per day composite end-point ischemic event diabetic patient acute coronary syndrome . Secondary objective : - To compare treatment enteric coat aspirin twice day ( 100 mg morning 100 mg evening ) versus enteric coat aspirin 100 mg per day net clinical benefit combine ischemic bleeding event diabetic patient acute coronary syndrome . - To compare treatment enteric coat aspirin twice day ( 100 mg morning 100 mg evening ) versus enteric coat aspirin 100 mg per day cardiac event diabetic patient acute coronary syndrome . - To compare treatment enteric coat aspirin twice day ( 100 mg morning 100 mg evening ) versus enteric coat aspirin 100 mg per day individual component main criterion . - To confirm safety innovative strategy ( aspirin twice day ) concern major bleed event . Study enrollment : Multicentric national study involve 42 center France The duration expect 24 month recruitment . Diabetic patient randomize index hospitalization acute coronary syndrome discharge conventional strategy enteric coat aspirin 100mg per day standard care innovative strategy enteric coat aspirin 100mg morning evening . Patients follow one month , six month , one year 18 month Statistical analysis : The study include 2574 diabetic patient . We hypothesize 18 month , event rate 22 % `` death , MI , stroke , urgent revascularization , acute arterial thrombotic event group treat aspirin expect decrease primary event 20 % ( relative variation ) use aspirin twice day corresponding event rate 17.6 % . A sample size 1287 patient /group allow 80 % power detect difference use log-rank test two-sided 5 % significance level . The study include 2574 diabetic patient . The primary analysis base Intention To Treat population primary endpoint . The primary analysis primary endpoint carry use log-rank test survival analysis . The 95 % confidence interval hazard ratio present . In addition survival status 18 month follow-up described show Kaplan-Meier curve . Primary outcome accord pre-specified subgroup : - Age : patient &lt; 75 year patient ≥75 year - Gender : male female - Insulin vs insulin treatment - Type acute coronary syndrome : STEMI v NSTEMI - Type ADP inhibitor cotreatment - Treatment strategy medical v invasive ( angioplasty CABG surgery ) - Peripheral artery disease Yes/No - GRACE score &gt; ≤140 - Left ventricular ejection fraction &gt; ≤ 40 % - Prior stroke Yes/No - previous treatment aspirin Yes/No - initial HbA1C level &gt; ≤8 % - duration diabetes &gt; ≤10 year - Weight &lt; 60 ; 60-90 ; &gt; 90kg - PPI use Yes/No</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<criteria>Diabetes mellitus define ( ≥ 1 item ) Treated diabetes mellitus 2 fast glucose level &gt; 7 mmol/l admission glucose level &gt; 11 mmol/l admission ( moment ) HbA1C ≥ 6.5 % Acute coronary syndrome define Acute coronary syndrome STsegment elevation ( STEMI ) define chest pain ( &gt; 30min ) persistent STsegment elevation least two contiguous lead ( ≥1mm ) new leave bundlebranch block intention perform primary PCI thrombolysis . Acute coronary syndrome without STsegment elevation ( NSTEMI ) define universal myocardial definition : Detection cardiac biomarker value elevation [ preferably cardiac troponin ( cTn ) ] least one value 99th percentile upper reference limit ( URL ) least one following : Symptoms ischemia New presumed new significant STsegmentT wave ( STT ) change except ST elevation Development pathological Q wave ECG Imaging evidence new loss viable myocardium new regional wall motion abnormality Identification intracoronary thrombus angiography include angiography show stenosis≥50 % discharge sign informed consent ≥18 year old Allergy contraindication aspirin ( Hypersensitivity aspirin excipients , history asthma induced administration salicylate , ongoing peptic ulcer , constitutional acquire haemorrhagic disease include gastrointestinal bleeding , history hemorrhagic stroke thrombocytopenia , pregnancy 24 week gestation , risk bleeding , severe renal failure , severe hepatic impairment , uncontrolled severe heart failure Concomitant anticoagulation therapy stop Fibrinolytic therapy le 24 hour . Unstable patient accord investigator : use amine mechanical device ( IABP , ECMO similar ) mechanical ventilation index hospitalization Index event acute complication coronary revascularization ( PCI CABG ) Known serious hematological disorder Proven gastric duodenal ulcer past 3 month Previous hemorrhagic stroke , previous cranial bleeding , intracranial neoplasia , arteriovenous malformation Any condition may put patient risk influence study result investigator ' opinion ( active cancer … . ) increase risk noncompliance lose followup Concomitant treatment methotrexate chronic nonsteroidal antiinflammatory drug Pregnancy lactation woman childbearing age without contraception Participant another investigational drug study within 30 day Patients curatorship No social security</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Diabetes mellitus</keyword>
	<keyword>Acute coronary syndrome</keyword>
	<keyword>Coronary artery disease</keyword>
	<keyword>Aspirin</keyword>
	<keyword>Secondary prevention</keyword>
</DOC>